NZ723827A - A method of manufacturing a stabilised complex of corticotropin releasing hormone (crh) and alpha-2 macroglobulin - Google Patents
A method of manufacturing a stabilised complex of corticotropin releasing hormone (crh) and alpha-2 macroglobulinInfo
- Publication number
- NZ723827A NZ723827A NZ72382713A NZ72382713A NZ723827A NZ 723827 A NZ723827 A NZ 723827A NZ 72382713 A NZ72382713 A NZ 72382713A NZ 72382713 A NZ72382713 A NZ 72382713A NZ 723827 A NZ723827 A NZ 723827A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crh
- serum
- macroglobulin
- alpha
- filtered
- Prior art date
Links
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 title abstract 8
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title abstract 8
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 title abstract 8
- 229940041967 corticotropin-releasing hormone Drugs 0.000 title abstract 8
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 title abstract 8
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 title abstract 3
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 abstract 8
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 230000000521 hyperimmunizing effect Effects 0.000 abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000011166 aliquoting Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 238000001471 micro-filtration Methods 0.000 abstract 1
- 238000001728 nano-filtration Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a CRH formulation having improved stability / efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also or alternatively relates to a method of producing the CRH formulation. In a particular embodiment, the invention relates to a method of manufacturing a stabilised complex of corticotropin releasing hormone (CRH) and alpha-2 macroglobulin, the method comprising: (a) providing hyperimmune serum from an ungulate that has been immunised with an immunodeficiency virus; (b) subjecting said hyperimmune serum to a microfiltration step that removes molecules having a size greater than 0.2 microns, thereby providing a micro-filtered serum; (c) subjecting said micro-filtered serum to a nanofiltration step that removes molecules having a size greater than 35 nanometres, thereby providing a nano-filtered serum; (d) aliquoting said nano-filtered serum into a vial, wherein said nano-filtered serum is in a form for administration to a patient and comprises the stabilised complex of CRH and alpha-2 macroglobulin; wherein the serum remains unfrozen throughout steps (b) to (d). The present invention also or alternatively relates to methods of treatment using said CRH formulation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1211247.0A GB201211247D0 (en) | 2012-06-25 | 2012-06-25 | Improved formulation |
| GB201221741 | 2012-12-03 | ||
| NZ70327113 | 2013-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ723827A true NZ723827A (en) | 2019-09-27 |
Family
ID=68318660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ72382713A NZ723827A (en) | 2012-06-25 | 2013-03-05 | A method of manufacturing a stabilised complex of corticotropin releasing hormone (crh) and alpha-2 macroglobulin |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ723827A (en) |
-
2013
- 2013-03-05 NZ NZ72382713A patent/NZ723827A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007147A (en) | A method of reducing brain amyloid plaques using anti-aã antibodies. | |
| WO2014004436A3 (en) | Crystalline anti-human il-23 antibodies | |
| WO2014160463A8 (en) | Prefusion rsv f proteins and their use | |
| WO2012149365A3 (en) | Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies | |
| WO2010111633A3 (en) | Antibody composition with altered fab sialylation | |
| WO2016037154A8 (en) | Recombinant hiv-1 envelope proteins and their use | |
| WO2013106577A3 (en) | Enhancement of transport of therapeutic molecules across the blood brain barrier | |
| WO2012106303A1 (en) | Pharmaceutical formulations including an amine compound | |
| NZ705370A (en) | Fcγriib-specific fc region variant | |
| AR081427A1 (en) | METHOD FOR PREPARING ANTIBODIES WITH IMPROVED PROPERTIES | |
| WO2014159822A3 (en) | Human antibodies to respiratory syncytial virus f protein and methods of use thereof | |
| NZ703298A (en) | Prostate-specific membrane antigen antibody drug conjugates | |
| BR112012022223A2 (en) | concentrated protein formulations and uses thereof | |
| WO2014031694A3 (en) | Anti-tau antibodies and methods of making and using in treatment of tauopathies | |
| BR112016010454A2 (en) | methods to treat a taupathy | |
| MX2009011897A (en) | Formulation of sugar solutions for continuous ultracentrifugation for virus purification. | |
| BR112014004828A2 (en) | A method for preparing a composition comprising highly concentrated ultrafiltration antibodies. | |
| WO2012145238A3 (en) | Methods for reducing an adverse immune response to a foreign antigen in human using cd4-binding molecules | |
| UA117228C2 (en) | Treatment for rheumatoid arthritis | |
| AR102096A1 (en) | PROCESS TO PREPARE GLATIRAMER ACETATE | |
| EA201691734A1 (en) | METHOD OF OBTAINING A STABLE SOLUTION FOR INJECTION WITH LOW CONCENTRATION OF NORADRENALINE | |
| AR082257A1 (en) | COMPOSITION OF CONCENTRATED HUMAN IMMUNOGLOBULINS, PROCEDURE | |
| AR094291A1 (en) | INJECTABLE FORMULATION OF PROLONGED RELEASE THAT INCLUDES OPTICALLY ACTIVE TOLVAPTAN, AND A PROCEDURE TO PRODUCE | |
| MX2016008397A (en) | Composition for use in the treatment of persistent cough. | |
| MX2016008498A (en) | Method for purifying antibody having low isoelectric point. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2021 BY ALICIA RAMSAY Effective date: 20200828 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2022 BY MARTIN HUNTER Effective date: 20210903 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2023 BY MURGITROYD + CO Effective date: 20220714 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2024 BY MURGITROYD + CO Effective date: 20230426 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 MAR 2025 BY ABBY SHERLOCK Effective date: 20240228 |